Vertex is extending its lead in the cystic fibrosis space and setting a premium price for its next-generation triple-combination product Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), which it intends to gradually replace its blockbuster Trikafta (elexacaftor/tezacaftor/ivacaftor). The Boston-based company set a wholesale acquisition cost (WAC) of $370,269 a year for Alyftrek, roughly a 7% premium over Trikafta’s US pricing.
Vertex New CF Combo Addresses More Patients, With Daily Dosing
Vertex hopes to convert CF patients to new combo Alyftrek from Trikafta with once-daily dosing. Approved on 20 December, the new triplet has longer patent protection and 7% higher US pricing.
